The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
Open accessAbstract
BACKGROUND: Type 1 diabetes is a chronic autoimmune disease that leads to destruction of insulin-producing beta cells and dependence on exogenous insulin for survival. Some interventions have delayed the loss of insulin production in patients with type 1 diabetes, but interventions that might affect clinical progression before diagnosis are needed. METHODS: We conducted a phase 2, randomized, placebo-controlled, double-blind trial of teplizumab (an Fc receptor-nonbinding anti-CD3 monoclonal antibody) involving relatives of patients with type 1 diabetes who did not have diabetes but were at high risk for development of clinical disease. Patients were randomly assigned to a single 14-day course of teplizumab or placebo, and follow-up for progression to clinical type 1 diabetes was performed with the use of oral glucose-tolerance tests at 6-month intervals. RESULTS: A total of 76 participants (55 [72%] of whom were ≤18 years of age) underwent randomization - 44 to the teplizumab group and 32 to the placebo group. The median time to the diagnosis of type 1 diabetes was 48.4 months in the teplizumab group and 24.4 months in the placebo group; the disease was diagnosed in 19 (43%) of the participants who received teplizumab and in 23 (72%) of those who received placebo. The hazard ratio for the diagnosis of type 1 diabetes (teplizumab vs. placebo) was 0.41 (95% confidence interval, 0.22 to 0.78; P = 0.006 by adjusted Cox proportional-hazards model). The annualized rates of diagnosis of diabetes were 14.9% per year in the teplizumab group and 35.9% per year in the placebo group. There were expected adverse events of rash and transient lymphopenia. KLRG1+TIGIT+CD8+ T cells were more common in the teplizumab group than in the placebo group. Among the participants who were HLA-DR3-negative, HLA-DR4-positive, or anti-zinc transporter 8 antibody-negative, fewer participants in the teplizumab group than in the placebo group had diabetes diagnosed. CONCLUSIONS: Teplizumab delayed progression to clinical type 1 diabetes in high-risk participants. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT01030861.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Family history of autoimmune diabetes and personal or family history of allergic diseases or other autoimmune diseases increases the risk of autoimmune diabetes compared with the general population (78,79).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, anti-CD3 treatment (teplizumab) has been shown to induce long-term protection (currently up to six years) from T1D in at-risk individuals, but the mechanisms responsible for this long-term protection remain incompletely understood29,30”
From An autoimmune stem-like CD8 T cell population drives type 1 diabetes (2022) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The CD3 monoclonal antibody teplizumab has been shown to delay progression to type 1 diabetes in high-risk individuals (429).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [429]
The cited source says what the claim attributes to it.
In the citing paper
“there is now evidence that the anti-CD3 monoclonal antibody teplizumab delays progression to type 1 diabetes in high-risk individuals (429).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [429]
The cited source says what the claim attributes to it.
In the citing paper
“In one 2019 study with a 2year delay, annualised rates of clinical diabetes were 15% in the teplizumab group and 36% in the placebo group (table 1). 18”
From The future of type 1 diabetes therapy (2025) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Teplizumab delays the onset of clinical type 1 diabetes by a median of 24 months.18”
From The future of type 1 diabetes therapy (2025) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2019
(2018) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,855
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.006 · Cited by 1,355
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254 · cited 2×
“Three participants in the teplizumab group and 4 participants in the placebo group did not complete the trial regimen; the reasons were laboratory abnormalities (4 participants), an inability to have intravenous access established (2), or rash (1).”
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s002 · Cited by 4,792
2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gaglia, J. L., Hilliard, M. E., Isaacs, D. M., et al. (2022) · Diabetes Care · doi:10.2337/dc23-s002 · Cited by 2,841
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s002 · Cited by 2,086
2. Diagnosis and classification of diabetes: standards of care in diabetes-2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Ebekozien, O., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s002 · Cited by 1,393
Pancreatic β-cells in type 1 and type 2 diabetes mellitus: different pathways to failure
Eizirik, D. L., Pasquali, L., & Cnop, M. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0355-7 · Cited by 854
Pathogenesis of autoimmune disease
Pisetsky, D. S. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00720-1 · Cited by 715
Global evolution of inflammatory bowel disease across epidemiologic stages
Hracs, L., Windsor, J. W., Gorospe, J., Cummings, M., Coward, S., Buie, M. J., Quan, J., Goddard, Q., Caplan, L., Markovinović, A., et al. (2025) · Nature · doi:10.1038/s41586-025-08940-0 · Cited by 533
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s002 · Cited by 473
Kaplon, H., Muralidharan, M., Schneider, Z., & Reichert, J. M. (2019) · mAbs · doi:10.1080/19420862.2019.1703531 · Cited by 431
Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases
Fugger, L. H., Jensen, L. T., & Rossjohn, J. (2020) · Cell · doi:10.1016/j.cell.2020.03.007 · Cited by 415
Chung, W. K., Erion, K., Florez, J. C., Hattersley, A. T., Hivert, M.-F., Lee, C. G., McCarthy, M. I., Nolan, J. J., Norris, J. M., Pearson, E. R., et al. (2020) · Diabetes Care · doi:10.2337/dci20-0022 · Cited by 400
Global burden of inflammatory bowel disease
Jairath, V., & Feagan, B. G. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30358-9 · Cited by 381
Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals
Sims, E. K., Bundy, B. N., Stier, K., Serti, E., Lim, N., Long, S. A., Geyer, S. M., Moran, A., Greenbaum, C. J., Evans-Molina, C., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc8980 · Cited by 377
Self-citationSacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Diabetes Care · doi:10.2337/dci23-0036 · Cited by 351
Battaglia, M., Ahmed, S., Anderson, M. S., Atkinson, M. A., Becker, D., Bingley, P. J., Bosi, E., Brusko, T. M., DiMeglio, L. A., Evans-Molina, C., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0880 · Cited by 351
Self-citationYield of a public health screening of children for islet autoantibodies in Bavaria, Germany
Ziegler, A.-G., Kick, K., Bonifacio, E., Haupt, F., Hippich, M., Dunstheimer, D., Lang, M., Laub, O., Warncke, K., Lange, K., et al. (2020) · JAMA · doi:10.1001/jama.2019.21565 · Cited by 312
Self-citationRobertson, C. C., Inshaw, J. R. J., Onengut-Gumuscu, S., Chen, W.-M., Santa Cruz, D. F., Yang, H., Cutler, A. J., Crouch, D. J. M., Farber, E., Bridges, S. L., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00880-5 · Cited by 302
Self-citationDiabetes mellitus—Progress and opportunities in the evolving epidemic
Abel, E. D., Gloyn, A. L., Evans‐Molina, C., Joseph, J. J., Misra, S., Pajvani, U. B., Simcox, J., Suszták, K., & Drucker, D. J. (2024) · Cell · doi:10.1016/j.cell.2024.06.029 · Cited by 350
Diabetes mellitus – Definition, Klassifikation, Diagnose, Screening und Prävention (Update 2023)
Harreiter, J., & Roden, M. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-022-02122-y · Cited by 352
The science and medicine of human immunology
Pulendran, B., & Davis, M. M. (2020) · Science · doi:10.1126/science.aay4014 · Cited by 275
Teplizumab and β-cell function in newly diagnosed type 1 diabetes
Ramos, E. L., Dayan, C. M., Chatenoud, L., Sumnik, Z., Simmons, K. M., Szypowska, A., Gitelman, S. E., Knecht, L. A., Niemoeller, E., Tian, W., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2308743 · Cited by 273
Self-citationNew frontiers in the treatment of type 1 diabetes
Warshauer, J. T., Bluestone, J. A., & Anderson, M. S. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.017 · Cited by 259
Self-citationRheumatoid Arthritis Pathogenesis, Prediction, and Prevention: An Emerging Paradigm Shift
Deane, K. D., & Holers, V. M. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41417 · Cited by 273
An autoimmune stem-like CD8 T cell population drives type 1 diabetes
Gearty, S. V., Dündar, F., Zumbo, P., Espinosa-Carrasco, G., Shakiba, M., Sanchez-Rivera, F. J., Socci, N. D., Trivedi, P., Lowe, S. W., Lauer, P., et al. (2022) · Nature · doi:10.1038/s41586-021-04248-x · Cited by 257
Syed, F. Z. (2022) · Annals of Internal Medicine · doi:10.7326/aitc202203150 · Cited by 289
Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective
Sims, E. K., Besser, R. E. J., Dayan, C. M., Rasmussen, C. G., Greenbaum, C. J., Griffin, K., Hagopian, W., Knip, M., Long, A. E., Martin, F., et al. (2022) · Diabetes · doi:10.2337/dbi20-0054 · Cited by 274
Self-citationQuattrin, T., Mastrandrea, L. D., & Walker, L. S. K. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00223-4 · Cited by 292
9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
Targeting co-stimulatory molecules in autoimmune disease
Edner, N. M., Carlesso, G., Rush, J. S., & Walker, L. S. K. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0081-9 · Cited by 232
The immunology of type 1 diabetes
Herold, K. C., Delong, T., Perdigoto, A. L., Biru, N., Brusko, T. M., & Walker, L. S. K. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-023-00985-4 · Cited by 241
Self-citationImmunotherapy: Building a bridge to a cure for type 1 diabetes
Bluestone, J. A., Buckner, J. H., & Herold, K. C. (2021) · Science · doi:10.1126/science.abh1654 · Cited by 221
Self-citation3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gaglia, J. L., Hilliard, M. E., Isaacs, D. M., et al. (2022) · Diabetes Care · doi:10.2337/dc23-s003 · Cited by 220
Chung, W. K., Erion, K., Florez, J. C., Hattersley, A. T., Hivert, M.-F., Lee, C. G., McCarthy, M. I., Nolan, J. J., Norris, J. M., Pearson, E. R., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05181-w · Cited by 203
von Herrath, M., Bain, S. C., Bode, B., Clausen, J. O., Coppieters, K., Gaysina, L., Gumprecht, J., Hansen, T. K., Mathieu, C., Morales, C., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00019-x · Cited by 186
Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes
Quandt, Z., Young, A., & Anderson, M. S. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13424 · Cited by 192
Overcoming barriers to early disease intervention
Caicedo, H. H., Hashimoto, D. A., Caicedo, J. C., Pentland, A., & Pisano, G. P. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0550-z · Cited by 181
Heterogeneity and endotypes in type 1 diabetes mellitus
REDONDO, M. J., & Morgan, N. G. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00853-0 · Cited by 182
TIGI study team, Leete, P., Oram, R. A., McDonald, T. J., Shields, B. M., Ziller, C., Hattersley, A. T., Richardson, S. J., & Morgan, N. G. (2020) · Diabetologia · doi:10.1007/s00125-020-05115-6 · Cited by 171
Autoreactive CD8+ T cell exhaustion distinguishes subjects with slow type 1 diabetes progression
Wiedeman, A. E., Muir, V. S., Rosasco, M. G., DeBerg, H. A., Presnell, S., Haas, B., Dufort, M. J., Speake, C., Greenbaum, C. J., Serti, E., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126595 · Cited by 168
Self-citationRech, J., Taşçılar, K., Hagen, M., Kleyer, A., Manger, B., Schönau, V., Hueber, A. J., Kleinert, S., Baraliakos, X., Braun, J., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02650-8 · Cited by 154
Type 1 diabetes mellitus: much progress, many opportunities
Powers, A. C. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142242 · Cited by 172
Sacks, D. B., Arnold, M. A., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad080 · Cited by 164
The global burden of inflammatory bowel disease: from 2025 to 2045
Kaplan, G. G. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01097-1 · Cited by 171
Haller, M. J., Bell, K. J., Besser, R. E. J., Casteels, K., Couper, J. J., Craig, M. E., Elding Larsson, H., Jacobsen, L., Lange, K., Oron, T., et al. (2024) · Hormone Research in Paediatrics · doi:10.1159/000543035 · Cited by 151
Self-citation3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2025
ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Early, K. B., Bruemmer, D., Ebekozien, O. A., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2024) · Diabetes Care · doi:10.2337/dc25-s003 · Cited by 171
Targeted pharmacological therapy restores β-cell function for diabetes remission
Sachs, S., Bastidas-Ponce, A., Tritschler, S., Bakhti, M., Böttcher, A., Sánchez-Garrido, M. A., Tarquis-Medina, M., Kleinert, M., Fischer, K., Jall, S., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0171-3 · Cited by 147
Besser, R. E. J., Bell, K. J., Couper, J., Ziegler, A., Wherrett, D. K., Knip, M., Speake, C., Casteels, K., Driscoll, K. A., Jacobsen, L. M., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13410 · Cited by 161
Self-citation3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2024
ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2023) · Diabetes Care · doi:10.2337/dc24-s003 · Cited by 157
Current and future therapies for type 1 diabetes
von Scholten, B. J., Kreiner, F. F., Gough, S. C. L., & von Herrath, M. (2021) · Diabetologia · doi:10.1007/s00125-021-05398-3 · Cited by 159
Khoryati, L., Pham, M. N., Sherve, M., Kumari, S., Cook, K. D., Pearson, J. T., Bogdani, M., Campbell, D., & Gavin, M. A. (2020) · Science Immunology · doi:10.1126/sciimmunol.aba5264 · Cited by 142
Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function
Herold, K. C., Gitelman, S. E., Gottlieb, P. A., Knecht, L. A., Raymond, R. H., & Ramos, E. L. (2023) · Diabetes Care · doi:10.2337/dc23-0675 · Cited by 151
Self-citationCost and cost-effectiveness of large-scale screening for type 1 diabetes in Colorado
McQueen, R. B., Geno Rasmussen, C., Waugh, K., Frohnert, B. I., Steck, A. K., Yu, L., Baxter, J., & Rewers, M. (2020) · Diabetes Care · doi:10.2337/dc19-2003 · Cited by 138
Atkinson, M. A., & Mirmira, R. G. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.06.018 · Cited by 139
Anti-Islet Autoantibodies in Type 1 Diabetes
Kawasaki, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210012 · Cited by 147
Deciphering the different phases of preclinical inflammatory bowel disease
Rudbaek, J. J., Agrawal, M., Torres, J., Mehandru, S., Colombel, J., & Jess, T. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00854-4 · Cited by 135
Tolerance in the Age of Immunotherapy
Bluestone, J. A., & Anderson, M. S. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1911109 · Cited by 137
Self-citation(2021) · Diabetes Care · doi:10.2337/dc21-ad09 · Cited by 135
Bieber, K., Hundt, J. E., Yu, X., Ehlers, M., Petersen, F., Karsten, C. M., Köhl, J., Kridin, K., Kalies, K., Kasprick, A., et al. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103236 · Cited by 135
Engineering islets from stem cells for advanced therapies of diabetes
Siehler, J., Blöchinger, A. K., Meier, M., & Lickert, H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00262-w · Cited by 125
Strategies for durable β cell replacement in type 1 diabetes
Brusko, T. M., Russ, H. A., & Stabler, C. L. (2021) · Science · doi:10.1126/science.abh1657 · Cited by 119
Abdelsamed, H. A., Zebley, C. C., Nguyen, H., Rutishauser, R. L., Fan, Y., Ghoneim, H. E., Crawford, J. C., Alfei, F., Alli, S., Ribeiro, S. P., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0633-5 · Cited by 121
Nakayasu, E. S., Syed, F., Tersey, S. A., Gritsenko, M. A., Mitchell, H. D., Chan, C. Y., Dirice, E., Turatsinze, J., Cui, Y., Kulkarni, R., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.12.005 · Cited by 116
Rebalancing Immune Homeostasis to Treat Autoimmune Diseases
Horwitz, D. A., Fahmy, T. M., Piccirillo, C. A., & Cava, A. L. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.08.003 · Cited by 122
Common genetic factors among autoimmune diseases
Harroud, A., & Hafler, D. A. (2023) · Science · doi:10.1126/science.adg2992 · Cited by 112
Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions
Abdeldaim, D. T., & Schindowski, K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102402 · Cited by 123
Prediction and Prevention of Type 1 Diabetes
Primavera, M., Giannini, C., & Chiarelli, F. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00248 · Cited by 130
Rosenzwajg, M., Salet, R., Lorenzon, R., Tchitchek, N., Roux, A., Bernard, C., Carel, J., Storey, C., Polak, M., Beltrand, J., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05200-w · Cited by 106
Cai, E. P., Ishikawa, Y., Zhang, W., Leite, N. C., Li, J., Hou, S., Kiaf, B., Hollister‐Lock, J., Yılmaz, N. K., Schiffer, C. A., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0254-1 · Cited by 107
Preventing type 1 diabetes in childhood
Dayan, C. M., Besser, R. E. J., Oram, R. A., Hagopian, W., Vatish, M., Bendor-Samuel, O., Snape, M. D., & Todd, J. A. (2021) · Science · doi:10.1126/science.abi4742 · Cited by 102
Steck, A. K., Dong, F., Rasmussen, C. G., BAUTISTA, K. A., Sepulveda, F., Baxter, J., Yu, L., Frohnert, B. I., & Rewers, M. (2021) · Diabetes Care · doi:10.2337/dc21-0602 · Cited by 105
Changing the landscape for type 1 diabetes: the first step to prevention
Dayan, C. M., Korah, M., Tatovic, D., Bundy, B. N., & Herold, K. C. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32127-0 · Cited by 96
Self-citationUnderstanding diabetes heterogeneity: key steps towards precision medicine in diabetes
Leslie, R. D., Ronald, C. W., Franks, P. W., Nadeau, K. J., Pearson, E. R., & REDONDO, M. J. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00159-6 · Cited by 112
Autoantibodies Targeting Intracellular and Extracellular Proteins in Autoimmunity
Burbelo, P. D., Iadarola, M. J., Keller, J. M., & Warner, B. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.548469 · Cited by 95
Why remission is not enough: underlying disease mechanisms in RA that prevent cure
Schett, G. A., Tanaka, Y., & Isaacs, J. D. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-00543-5 · Cited by 93
The immunopathogenesis of narcolepsy type 1
Liblau, R. S., Latorre, D., Kornum, B. R., Dauvilliers, Y., & Mignot, E. J. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-023-00902-9 · Cited by 91
From the prodromal stage of multiple sclerosis to disease prevention
Marrie, R. A., Allegretta, M., Barcellos, L. F., Bebo, B. F., Calabresi, P. A., Correale, J. D., Davis, B. G., Jager, P. L. D., Gasperi, C., Greenbaum, C. J., et al. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00686-x · Cited by 91
Self-citationNew advances in type 1 diabetes
Subramanian, S., Khan, F. N., & Hirsch, I. B. (2024) · BMJ · doi:10.1136/bmj-2023-075681 · Cited by 105
Gerace, D., Zhou, Q., Kenty, J. H.-R., Veres, A., Sintov, E., Wang, X., Boulanger, K. R., Li, H., & Melton, D. A. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100879 · Cited by 88
Preclinical rheumatoid arthritis and rheumatoid arthritis prevention
Greenblatt, H. K., Kim, H., Bettner, L. F., & Deane, K. D. (2020) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000708 · Cited by 85
The Human Islet: Mini-Organ With Mega-Impact
Walker, J. T., Saunders, D. C., Briššová, M., & Powers, A. C. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab010 · Cited by 88
Phillip, M., Achenbach, P., Addala, A., Albanese-O’Neill, A., Battelino, T., Bell, K. J., Besser, R. E. J., Bonifacio, E., Colhoun, H. M., Couper, J. J., et al. (2024) · Diabetes Care · doi:10.2337/dci24-0042 · Cited by 79
Self-citationLee, S.-H., Turpin, W., Espin‐Garcia, O., Garay, J. A. R., Smith, M. I., Leibovitzh, H., Goethel, A., Turner, D., Mack, D. R., Deslandres, C., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.009 · Cited by 80
O’Neil, L. J., Alpizar-Rodriguez, D., & Deane, K. D. (2024) · The Journal of Rheumatology · doi:10.3899/jrheum.2023-0334 · Cited by 91
DYRK1A Inhibitors as Potential Therapeutics for β-Cell Regeneration for Diabetes
Kumar, K., Suebsuwong, C., Wang, P., Garcı́a-Ocaña, A., Stewart, A. F., & DeVita, R. J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02050 · Cited by 73
Weiß, A., Zapardiel‐Gonzalo, J., Voss, F., Jolink, M., Stock, J., Haupt, F., Kick, K., Welzhofer, T., Heublein, A., Winkler, C., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05780-9 · Cited by 79
Self-citationAdvances in Type 1 Diabetes Prediction Using Islet Autoantibodies: Beyond a Simple Count
So, M., Speake, C., Steck, A. K., Lundgren, M., Colman, P. G., Palmer, J. P., Herold, K. C., & Greenbaum, C. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab013 · Cited by 75
Self-citationTherapeutic Antibodies in Medicine
Sharma, P., Joshi, R. V., Pritchard, R., Xu, K., & Eicher, M. A. (2023) · Molecules · doi:10.3390/molecules28186438 · Cited by 81
Bogun, M. M., Bundy, B. N., Goland, R. S., & Greenbaum, C. J. (2020) · Diabetes Care · doi:10.2337/dc19-2288 · Cited by 72
Self-citationDiggins, K. E., Serti, E., MUIR, V. S., Rosasco, M. G., Lü, T., Balmas, E., Nepom, G. T., Long, S. A., & Linsley, P. S. (2020) · JCI Insight · doi:10.1172/jci.insight.142680 · Cited by 71
Self-citationTeplizumab approval for type 1 diabetes in the USA
Evans‐Molina, C., & Oram, R. A. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00390-4 · Cited by 77
Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes
Jacobsen, L. M., Bundy, B. N., Greco, M. N., Schatz, D., Atkinson, M. A., Brusko, T. M., Mathews, C. E., Herold, K. C., Gitelman, S. E., Krischer, J. P., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0305 · Cited by 71
Self-citationKumar, M., Yip, L., Wang, F., Marty, S., & Fathman, C. G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1626082 · Cited by 87
MOF-based platforms on diabetic disease: Advanced and prospect of effective diagnosing and therapy
Ma, D., Liang, T., Zheng, J., Chen, G., Ye, Y., Nezamzadeh‐Ejhieh, A., Lu, L., Song, Z., & Huang, Y. (2025) · Reactive and Functional Polymers · doi:10.1016/j.reactfunctpolym.2025.106520 · Cited by 72
Glycolysis Inhibition Induces Functional and Metabolic Exhaustion of CD4+ T Cells in Type 1 Diabetes
Martins, C. P., New, L. A., O’Connor, E. C., Previte, D. M., Cargill, K. R., Tse, I., Sims‐Lucas, S., & Piganelli, J. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669456 · Cited by 70
Phillip, M., Achenbach, P., Addala, A., Albanese-O’Neill, A., Battelino, T., Bell, K. J., Besser, R. E. J., Bonifacio, E. E., Colhoun, H. M., Couper, J., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06205-5 · Cited by 83
Self-citationFalcone, M., & Fousteri, G. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00569 · Cited by 72
Epidemiology of Type 1 Diabetes
Vanderniet, J. A., Jenkins, A. J., & Donaghue, K. C. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01762-w · Cited by 87
The beta cell-immune cell interface in type 1 diabetes (T1D)
James, E. A., Joglekar, A. V., Linnemann, A. K., Russ, H. A., & Kent, S. C. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101809 · Cited by 72
Wołosowicz, M., Łukaszuk, B., & Chabowski, A. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17228651 · Cited by 69
Two-age islet-autoantibody screening for childhood type 1 diabetes: a prospective cohort study
Ghalwash, M. F., Dunne, J. L., Lundgren, M., Rewers, M., Ziegler, A., Anand, V., Toppari, J., Veijola, R., & Hagopian, W. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00141-3 · Cited by 69
Self-citation
Metadata
- Authors
- Herold, K. C., Bundy, B. N., Long, S. A., Bluestone, J. A., DiMeglio, L. A., Dufort, M. J., Gitelman, S. E., Gottlieb, P. A., Krischer, J. P., Linsley, P. S., Marks, J. B., Moore, W., Moran, A., Rodriguez, H., Russell, W. E., Schatz, D., Skyler, J. S., Tsalikian, E., Wherrett, D. K., Ziegler, A.-G., & Greenbaum, C. J.
- Affiliations
- University of Miami (US)
- Children's Mercy Hospital (US)
- University of Minnesota (US)
- University of Iowa (US)
- ORCID
- Herold, Kevan C.
- Bundy, Brian N.
- Long, S. Alice
- Bluestone, Jeffrey A.
- DiMeglio, Linda A.
- Dufort, Matthew J.
- Gitelman, Stephen E.
- Gottlieb, Peter A.
- Krischer, Jeffrey P.
- Linsley, Peter S.
- Marks, Jennifer B.
- Moran, Antoinette
- Rodriguez, Henry
- Russell, William E.
- Schatz, Desmond
- Skyler, Jay S.
- Tsalikian, Eva
- Wherrett, Diane K.
- Ziegler, Anette-Gabriele
- Greenbaum, Carla J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-08-15
- Volume
- 381
- Issue
- 7
- Pages
- 603-613
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6776880
- OpenAlex
- W2948104235
- Semantic Scholar
- a5198a4024a6f0aecc74d1501dd9fd2892f98796
- Cited by
- 1,189
- References
- 48
- Citations by year
- 2026: 186 · 2025: 209 · 2024: 211 · 2023: 181 · 2022: 123 · 2021: 148 · 2020: 98 · 2019: 32
- FWCI
- 60.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK061010, U01 DK061034, U01 DK061042, U01 DK061058, U01 DK085461, U01 DK085465, U01 DK085466, U01 DK085476, U01 DK085499, U01 DK085509, U01 DK103266, U01 DK103282, U01 DK106984, U01 DK107013, U01 DK107014, UC4 DK085466, UC4 DK097835, UC4 DK106993)
- JDRF
- American Diabetes Association
- The Immune Tolerance Network (UM1 AI09565)
- National Center for Research Resources, through Clinical Translational Science Awards (UL1TR000064, UL1TR000114, UL1TR000142, UL1TR000445, UL1TR001082, UL1TR001857, UL1TR001872, UL1TR002366, UL1TR002529, UL1TR002537)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- teplizumab, anti-CD3 monoclonal antibody, type 1 diabetes prevention, high-risk relatives, TIGIT, HLA-DR3, HLA-DR4, zinc transporter 8 antibodies, islet autoimmunity, lymphopenia
- MeSH terms
- Adolescent, Adult, Child, Diabetes Mellitus, Type 1, Double-Blind Method, Exanthema, Female, Glucose Tolerance Test, Humans, Lymphopenia, Male, Middle Aged, T-Lymphocytes, HLA-DR3 Antigen, HLA-DR4 Antigen, Proportional Hazards Models, CD3 Complex, Disease Progression, Lymphocyte Count, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
